Table of Contents
1 STRATEGIC ANALYSIS OF BIOMARKERS IN CLINICAL TRIALS
Overview Research Scope & Methodology Introduction & Background
Market Dynamics
- Major Challenges for Biomarkers in Clinical Trials
- Key Market Trends
- Market Drivers
- Market Restraints
- Key Market Engineering Measurements
- Total Market Revenue Forecast
Regulatory Climate
- Drug Failure in Clinical Development
- Decrease in FDA Submissions
- Decrease in EMEA Submissions
- Current FDA Policy
Research Trends
- Assumptions
- World Biomarker Research Direction
- World Investment in Research and Development
- World Biomarker IP Portfolios
- Competitive Profiles
- Other Key Industry Participants
Major Challenges and Strategic Proposals
- Biomarker Misdiagnosis Issues
- Investment in Biomarkers
- Clinical Development Productivity Improvement
- Biomarker Regulatory Issues
- Late Stage Clinical Failure
- Summary of Strategic Proposals
Corporate Strategy
- Corporate Strategy--Strategic Anticipation
- Corporate Strategy--Market Maturation Process
- Corporate Strategy--Competitive Framework
- Corporate Strategy--Potential Threats
- Corporate Strategy--Meeting the Challenge
Frost & Sullivan Awards
- Frost & Sullivan Awards Description
- Growth Strategy Leadership Award
- Technology Leadership Award
- Entrepreneurial Company Award
- Market Leadership Award
- Competitive Strategy Leadership Award
Decision Support Databases
- New Drugs Approved by the FDA (2000-2004)
- New Drugs Approved by the EMEA (2000-2004)
- Number of Biotechnology Companies--Western Europe and North America
(1999-2006)
- Major Pharmaceutical Companies in Europe (2003)
- Biotechnology European Patents Filed (1996-2000)
- Governmental Biotechnology Investment (1999-2006)
- Pharmaceutical Research and Development Expenditure (1999-2006)
Frost & Sullivan
- Healthcare Team
- Our Capabilities
| 
View Cart
